Published online Jun 15, 2022. doi: 10.4251/wjgo.v14.i6.1216
Peer-review started: October 25, 2021
First decision: April 17, 2022
Revised: April 19, 2022
Accepted: April 22, 2022
Article in press: April 22, 2022
Published online: June 15, 2022
Processing time: 227 Days and 13.4 Hours
We rechecked the original data of Figure 3, Part.B, and found that 0 h group in the BGC-823 cell wound scratch assay was misapplied. Therefore, we are writing to apply for the modification of Figure 3, Part.B.
Core Tip: This is a correction to "MicroRNA-320a suppresses tumor progression by targeting PBX3 in gastric cancer and is downregulated by DNA methylation".
- Citation: Li YS, Zou Y, Dai DQ. Correction to "MicroRNA-320a suppresses tumor progression by targeting PBX3 in gastric cancer and is downregulated by DNA methylation". World J Gastrointest Oncol 2022; 14(6): 1216-1217
- URL: https://www.wjgnet.com/1948-5204/full/v14/i6/1216.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v14.i6.1216
Correction to: Li YS, Zou Y, Dai DQ. MicroRNA-320a suppresses tumor progression by targeting PBX3 in gastric cancer and is downregulated by DNA methylation. World J Gastrointest Oncol 2019; 11(10): 842-856 PMID:
We recently read our manuscript published in the World Journal of Gastrointestinal Oncology (Manuscript NO: 48527, DOI: 10.4251/wjgo.v11.i10.842), we have carefully rechecked the original data of Figure 3, Part.B, and found that 0 h group in the BGC-823 cell wound scratch assay was misapplied. Therefore, we are writing to apply for the modification of Figure 3, Part.B. The revised images are shown in this Correction (Figure 1). We feel deeply sorry for this mistake during the proofreading process. This correction does not alter any interpretation of the results or conclusion of this study[1].
We apologize for any inconvenience caused by this mistake.
| 1. | Li YS, Zou Y, Dai DQ. MicroRNA-320a suppresses tumor progression by targeting PBX3 in gastric cancer and is downregulated by DNA methylation. World J Gastrointest Oncol. 2019;11:842-856. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in CrossRef: 15] [Cited by in RCA: 16] [Article Influence: 2.3] [Reference Citation Analysis (0)] |
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Provenance and peer review: Unsolicited article; Externally peer reviewed.
Peer-review model: Single blind
Specialty type: Oncology
Country/Territory of origin: China
Peer-review report’s scientific quality classification
Grade A (Excellent): 0
Grade B (Very good): B, B
Grade C (Good): C
Grade D (Fair): 0
Grade E (Poor): 0
P-Reviewer: Hori T, Japan; Kapritsou M, Greece; Moshref L, Saudi Arabia S-Editor: Wang LL L-Editor: A P-Editor: Wang LL